InventHelp Inventor Develops Set of Pillows for Knee Bolstering (ASP-265)
PITTSBURGH, April 29, 2024 /PRNewswire/ -- "I've experienced intermittent back pain for years. I tried bolstering my knees, but I change sleeping positions throughout the night," said an inventor, from Round Rock, Texas, "so I invented THE SPINE ALIGN FOR SLEEP. My design enables you to easily maintain the knee bolstering while sleeping in different positions."
The invention provides an effective way to maintain knee bolstering throughout the night. In doing so, it enables the user to alter sleeping positions. As a result, it offers therapeutic benefits, and it helps reduce back pain. The invention features a practical design that is easy to use so it is ideal for back pain sufferers, pregnant women, people with disabilities, etc.
The original design was submitted to the Austin sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 22-ASP-265, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
Author Kory L. Wilson and his family have experienced the benefits of information he shares in Home Remedies: A Guidebook To Breaking Away From Big Pharma ($15.99, paperback, 9781662896668; $6.99, e-book, 9781662896675).
For years, I have collected...
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...
